Moderna is seeking for US and European emergency regulatory approval of its already tested coronavirus vaccine.
Regulators will consider the results of the previous trials and then decide if it is safe and effective enough to recommend for roll out.
Clinical studies show the jab is more than 94 per cent effective at protecting people from becoming ill with Covid-19.
Pfizer, which seems to be just as successful, has already filed for the US approval.
UK regulators will be reviewing data on both vaccines, as well as another type of Covid vaccine from AstraZenca and Oxford University for emergency approval.
Moderna says it hopes to gain UK approval soon, now that it has trial data from 30,000 volunteers – including high risk groups like the elderly – that suggests it works.
In those studies, 15,000 people received the real vaccine while the other participants got placebo injections. No serious side effects were reported.
During the studies, 185 people in the placebo group fell ill with COVID-19, and some severely so.
In comparison, there were 11 cases in the vaccine group and none were severe.
Full trial data has not been released yet.
By Olimpia Zagnat
Featured image: Olimpia Zagnat
Input Image by Gerd Altmann from Pixabay.